Indoleamine 2,3-dioxygenase activation and depressive symptoms: Results from the young finns study

Psychosomatic Medicine

Volumn 74, Issue 7, 2012, Pages 675-681

  Elovainio, Marko ^a,b   Hurme, Mikko ^d,e   Jokela, Markus ^a   Pulkki Råback, Laura ^a,c   Kivimäki, Mika ^a,c,h   Hintsanen, Mirka ^a   Hintsa, Taina ^a   Lehtimäki, Terho ^d,e   Viikari, Jorma ^f,g   Raitakari, Olli T ^f,g   Keltikangas Järvinen, Liisa ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

^f UNIVERSITY OF TURKU   (Finland)

^g TURKU UNIVERSITY HOSPITAL   (Finland)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

depressive symptoms; inflammation; longitudinal; serotonin; sex

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; SEROTONIN;

ADULT; ARTICLE; BODY MASS; DEPRESSION; ENZYME ACTIVATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; PRIORITY JOURNAL; RISK FACTOR;

EID: 84866332726     PISSN: 00333174     EISSN: 15347796     Source Type: Journal    
DOI: 10.1097/PSY.0b013e318266d0f5     Document Type: Article

References (44)

1. Leonard BE, Myint A. The psychoneuroimmunology of depression. Hum Psychopharmacol 2009;24:165-75.
2. Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008;358:55-68.
3. Maes M, Meltzer HY, D'Hondt P, Cosyns P, Blockx P. Effects of serotonin precursors on the negative feedback effects of glucocorticoids on hypothalamic-pituitary-adrenal axis function in depression. Psycho- neuroendocrinology 1995;20:149-67. (Pubitemid 24366197)
4. Ruhé HG, Mason NS, Schene AH. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 2007;12:331-59. (Pubitemid 46496835)
5. Oxenkrug GF. Tryptophan kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later. Isr J Psychiatry Relat Sci 2010;47:56-63.
6. Mellor AL, Baban B, Chandler P, Marshall B, Jhaver K, Hansen A, Koni PA, Iwashima M, Munn DH. Cutting edge: induced indoleamine 2, 3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 2003;171:1652-5. (Pubitemid 36966447)
7. Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G, Spivey JR, Saito K, Miller AH. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 2010;15: 393-403.
8. Mellor AL, Munn D, Chandler P, Keskin D, Johnson T, Marshall B, Jhaver K, Baban B. Tryptophan catabolism and T cell responses. Adv Exp Med Biol 2003;527:27-35. (Pubitemid 38197625)
9. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004;4:762-74. (Pubitemid 39336293)
10. Carlin JM, Ozaki Y, Byrne GI, Brown RR, Borden EC. Interferons and indoleamine 2, 3-dioxygenase: role in antimicrobial and antitumor effects. Experientia 1989;45:535-41. (Pubitemid 19151363)
11. Kiyohara C, Yoshimasu K. Association between major depressive disorder and a functional polymorphism of the 5-hydroxytryptamine (serotonin) transporter gene: a meta-analysis. Psychiatr Genet 2010;20:49-58.
12. Mossner R, Lesch KP. Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav Immun 1998;12:249-71. (Pubitemid 29224829)
13. Mossner R, Heils A, Stober G, Okladnova O, Daniel S, Lesch KP. Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6. Neurochem Int 1998;33:251-4. (Pubitemid 28418296)
14. Maes M, Verkerk R, Bonaccorso S, Ombelet W, Bosmans E, Scharpe S. Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation. Life Sci 2002;71:1837-48. (Pubitemid 34880232)
15. Miller CL, Llenos IC, Dulay JR, Weis S. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 2006; 1073-4:25-37.
16. Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, Weis S. Expression of the kynurenine pathway enzyme tryptophan 2, 3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis 2004;15:618-29. (Pubitemid 38429977)
17. Myint AM, Kim YK, Verkerk R, Park SH, Scharpe S, Steinbusch HW, Leonard BE. Tryptophan breakdown pathway in bipolar mania. J Affect Disord 2007;102:65-72. (Pubitemid 47042175)
18. Raitakari OT, Juonala M, Rönnemaa T, Keltikangas-Järvinen L, Räsänen L, Pietikäinen M, Hutri-Kähönen N, Taittonen L, Jokinen E, Marniemi J, Jula A, Telama R, Kähönen M, Lehtimäki T, Åkerblom HK, Viikari JS. Cohort profile: The Cardiovascular Risk in Young Finns Study. Int J Epidemiol 2008;37:1220-6.
19. Beck A. Depression. Clinical, Experimental and Theoretical Aspects. New York, NY: Harper & Row Publishers; 1967.
20. Katainen S, Räikkönen K, Keltikangas-Järvinen L. Adolescent temperament, perceived social support, and depressive tendencies as predictors of depressive tendencies in young adulthood. Eur J Pers 1999;13:183-207.
21. Elovainio M, Keltikangas-Jarvinen L, Kivimaki M, Pulkki L, Puttonen S, Heponiemi T, Juonala M, Viikari JS, Raitakari OT. Depressive symptoms and carotid artery intima-media thickness in young adults: The Cardiovascular Risk in Young Finns Study. Psychosom Med 2005;67:561-7. (Pubitemid 41033584)
22. Elovainio M, Kivimaki M, Puttonen S, Heponiemi T, Pulkki L, Keltikangas-Jarvinen L. Temperament and depressive symptoms: a population-based longitudinal study on Cloninger's psychobiological temperament model [comment]. J Affect Disord 2004;83:227-32. (Pubitemid 39536199)
23. Salmela-Aro K, Nurmi JE, Saisto T, Halmesmaki E. Goal reconstruction and depressive symptoms during the transition to motherhood: evidence from two cross-lagged longitudinal studies. J Pers Soc Psychol 2001;81: 1144-59. (Pubitemid 33594535)
24. Judd LL, Schettler PJ, Akiskal HS. The prevalence, clinical relevance, and public health significance of subthreshold depressions. Psychiatr Clin North Am 2002;25:685-98. (Pubitemid 35351201)
25. Aalto AM, Aro AR, Weinman J, Heijmans M, Manderbacka K, Elovainio M. Sociodemographic, disease status, and illness perceptions predictors of global self-ratings of health and quality of life among those with coronary heart diseaseVone year follow-up study. Qual Life Res 2006;15:1307-22. (Pubitemid 44673607)
26. Elovainio M, Keltikangas-Jarvinen L, Pulkki-Raback L, Kivimaki M, Puttonen S, Viikari L, Rasanen L, Mansikkaniemi K, Viikari J, Raitakari OT. Depressive symptoms and C-reactive protein: The Cardiovascular Risk in Young Finns Study. Psychol Med 2006;36:797-805. (Pubitemid 43744773)
27. Pertovaara M, Raitala A, Juonala M, Lehtimaki T, Huhtala H, Oja SS, Jokinen E, Viikari JS, Raitakari OT, Hurme M. Indoleamine 2, 3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: The Cardiovascular Risk in Young Finns Study. Clin Exp Immunol 2007;148:106-11. (Pubitemid 46364993)
28. Widner B, Werner E, Schennach H, Wachter H, Fuchs D. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem 1997;43:2424-6. (Pubitemid 28022985)
29. Laich A, Neurauter G, Widner B, Fuchs D. More rapid method for simultaneous measurement of tryptophan and kynurenine by HPLC. Clin Chem 2002;48:579-81. (Pubitemid 34174597)
30. Raitakari OT, Juonala M, Kahonen M, Taittonen L, Laitinen T, Maki-Torkko N, Jarvisalo MJ, Uhari M, Jokinen E, Ronnemaa T, Akerblom HK, Viikari JS. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: The Cardiovascular Risk in Young Finns Study. JAMA 2003;290:2277-83. (Pubitemid 37430560)
31. Niinisalo P, Raitala A, Pertovaara M, Oja SS, Lehtimaki T, Kahonen M, Reunanen A, Jula A, Moilanen L, Kesaniemi YA, Nieminen MS, Hurme M. Indoleamine 2, 3-dioxygenase activity associates with cardiovascular risk factors: the Health 2000 study. Scand J Clin Lab Invest 2008;68: 767-70.
32. Moroni F, Russi P, Carla V, De Luca G, Politi V. The regulation of brain kynurenic acid content: focus on indole-3-pyruvic acid. Adv Exp Med Biol 1991;294:299-308.
33. Wichers MC, Koek GH, Robaeys G, Praamstra AJ, Maes M. Early increase in vegetative symptoms predicts IFN-alphaYinduced cognitive-depressive changes. Psychol Med 2005;35:433-41. (Pubitemid 40372481)
34. Wichers MC, Kenis G, Leue C, Koek G, Robaeys G, Maes M. Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol Psychiatry 2006;60:77-9.
35. Wichers MC, Kenis G, Koek GH, Robaeys G, Nicolson NA, Maes M. Interferon-alphaYinduced depressive symptoms are related to changes in the cytokine network but not to cortisol. J Psychosom Res 2007;62:207-14. (Pubitemid 46161588)
36. Douglas KM, Taylor AJ, O'Malley PG. Relationship between depression and C-reactive protein in a screening population. Psychosom Med 2004; 66:679-83. (Pubitemid 39332353)
37. Elovainio M, Aalto AM, Kivimaki M, Pirkola S, Sundvall J, Lonnqvist J, Reunanen A. Depression and C-reactive protein: population-based Health 2000 study. Psychosom Med 2009;71:423-30.
38. Xiao BG, Liu X, Link H. Antigen-specific T cell functions are suppressed over the estrogen-dendritic cell-indoleamine 2, 3-dioxygenase axis. Steroids 2004;69:653-9. (Pubitemid 39297704)
39. Widner B, Sepp N, Kowald E, Ortner U, Wirleitner B, Fritsch P, Baier-Bitterlich G, Fuchs D. Enhanced tryptophan degradation in systemic lupus erythematosus. Immunobiology 2000;201:621-30. (Pubitemid 30242927)
40. Pertovaara M, Heliovaara M, Raitala A, Oja SS, Knekt P, Hurme M. The activity of the immunoregulatory enzyme indoleamine 2, 3-dioxygenase is decreased in smokers. Clin Exp Immunol 2006;145:469-73. (Pubitemid 44252489)
41. Onalan G, Onalan R, Selam B, Akar M, Gunenc Z, Topcouglu A. Mood scores in relation to hormone replacement therapies during menopause: a prospective rendomized trial. Tohoku J Exp Med 2005;207:223-31. (Pubitemid 41601053)
42. Manson J. Post menopausal hormone therapy and atherosclerotic disease. Am Heart J 2002;128:1337-43.
43. Katainen S. Temperament and Development: A Longitudinal Study of Temperament-Mothering Interaction and the Development of Temperament, Depressive Tendencies and Hostility [doctoral dissertation]. Helsinki, Finland: University of Helsinki; 1999. Research Reports No. 20.
44. Petersen AC, Compas BE, Brooks-Gunn J, Stemmler M, Ey S, Grant KE. Depression in adolescence. Am Psychol 1993;48:155-68.